- A previously reported Lymphoid Malignancies Branch (LYMB) trial administering alemtuzumab (CAMPATH-1) to patients with chronic, acute and lymphomatous subtype HTLV-1 associated ATL showed appreciable initial activity but no clear long-term impact.